MeiraGTx Holdings plc

NASDAQ•MGTX

CEO: Dr. Alexandria Forbes Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2018-06-08

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Contact Information

450 East 29th Street, 14th Floor, New York, NY, 10016, United States

646-860-7985

meiragtx.com

Market Cap

$596.44M

P/E (TTM)

-3.6

19.7

Dividend Yield

52W High

$9.73

52W Low

$4.55

52W Range

55%

Rank67Top 97.6%

1.4

F-Score

Modified Piotroski Analysis

Based on 9-year fundamentals

Weak • 1.4 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2017-2025

Financial Dashboard

Q3 2025 Data

Revenue

$410.00K-96.24%

4-Quarter Trend

EPS

-$0.62+12.73%

4-Quarter Trend

FCF

-$12.83M-50.20%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Hologen Strategic Collaboration Closed Received $28.0M deposit from Hologen; joint venture established for AAV-GAD Parkinson's program development.

Lilly Ophthalmology Deal Signed Secured exclusive worldwide rights for AAV-AIPL1; eligible for $75.0M upfront payment plus $400.0M milestones.

Service Revenue Significantly Decreased Nine-month service revenue fell $5.9M to $6.0M USD as PPQ services under Asset Purchase Agreement substantially completed.

RMAT Designations Secured Received FDA RMAT designation for AAV-hAQP1 (xerostomia) and AAV-GAD (Parkinson's), potentially accelerating review timelines.

Risk Factors

Persistent Operating Losses Incurred Accumulated deficit reached $831.3M USD as of September 30, 2025; expects substantial losses for foreseeable future.

Future Capital Requirements High Requires substantial additional financing for development; failure to raise capital risks delaying or eliminating key research and development programs.

Gene Therapy Regulatory Uncertainty Novel gene therapy platform faces uncertain regulatory landscape; predicting development time and cost remains difficult.

Manufacturing Capacity Constraints Reliance on third-party plasmid suppliers and internal facilities carries risk of delays or inability to meet regulatory requirements or commercial scale.

Outlook

Advance AAV-GAD Phase 3 Study Engaging global sites to initiate Phase 3 study for AAV-GAD Parkinson's treatment in the coming months following RMAT designation.

AAV-hAQP1 Pivotal Data Expected Phase 2 AQUAx2 study enrolling final cohorts; potential pivotal data readout supporting BLA filing targeted for early 2027.

Expand Riboswitch Platform Into Clinic Progressing first riboswitch program (human leptin) into clinic; demonstrated dose-response efficacy in mouse models over one year.

Cash Runway Extended to 2027 Estimated cash sufficient to fund operations into second half of 2027, supported by Lilly and Hologen funding milestones.

Peer Comparison

Revenue (TTM)

IOVA

$263.50M

+60.6%

ARVN

$262.60M

-0.3%

DNA

$170.16M

-25.1%

Gross Margin (Latest Quarter)

IOVA

215.9%

+65.9pp

DNA

124.4%

-21.7pp

ATXS

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ERAS	$4.68B	-33.6	-33.1%	11.5%
KOD	$1.42B	-6.5	-246.2%	28.5%
IOVA	$1.41B	-4.4	-54.5%	5.3%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-73.2%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 12, 2026

EPS:-$0.60

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data